- Home
- SCD vs SERA Comparison
SCD vs SERA Comparison
Compare SCD & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- SERA
- Stock Information
- Founded
- SCD 2003
- SERA 2008
- Country
- SCD United States
- SERA United States
- Employees
- SCD N/A
- SERA N/A
- Industry
- SCD Trusts Except Educational Religious and Charitable
- SERA Precision Instruments
- Sector
- SCD Finance
- SERA Health Care
- Exchange
- SCD Nasdaq
- SERA Nasdaq
- Market Cap
- SCD 259.3M
- SERA 258.3M
- IPO Year
- SCD N/A
- SERA 2021
- Fundamental
- Price
- SCD $17.40
- SERA $6.99
- Analyst Decision
- SCD
- SERA
- Analyst Count
- SCD 0
- SERA 0
- Target Price
- SCD N/A
- SERA N/A
- AVG Volume (30 Days)
- SCD 62.6K
- SERA 136.5K
- Earning Date
- SCD 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- SCD 9.63%
- SERA N/A
- EPS Growth
- SCD N/A
- SERA N/A
- EPS
- SCD N/A
- SERA N/A
- Revenue
- SCD N/A
- SERA $107,000.00
- Revenue This Year
- SCD N/A
- SERA N/A
- Revenue Next Year
- SCD N/A
- SERA $2,020.00
- P/E Ratio
- SCD N/A
- SERA N/A
- Revenue Growth
- SCD N/A
- SERA N/A
- 52 Week Low
- SCD $11.33
- SERA $1.56
- 52 Week High
- SCD $15.87
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- SCD 56.60
- SERA 42.00
- Support Level
- SCD $17.07
- SERA $6.25
- Resistance Level
- SCD $17.53
- SERA $7.27
- Average True Range (ATR)
- SCD 0.35
- SERA 0.49
- MACD
- SCD -0.08
- SERA -0.12
- Stochastic Oscillator
- SCD 46.07
- SERA 23.11
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.